Bacterial complement escape

Advances in Experimental Medicine and Biology

Volumn 666, Issue , 2009, Pages 32-48

  Jongerius, Ilse ^b   Ram, Sanjay ^b   Rooijakkers, Suzan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C9; CYSTEINE PROTEINASE IDES; CYSTEINE PROTEINASE SPEB; EXTRACELLULAR COMPLEMENT BINDING PROTEIN; EXTRACELLULAR FIBRINOGEN BINDING PROTEIN; FHL 1 BINDING PROTEIN; FIBRINOGEN; LIPOOLIGOSACCHARIDE; M PROTEIN; M RELATED PROTEIN 4; PLASMINOGEN; PROTEIN FBA; PROTEIN FH; PROTEIN FHL 1; PROTEIN SBI; PROTEIN SBI EXTRACELLULAR REGION; STAPHYLOCOCCAL SUPERANTIGEN LIKE PROTEIN 7; STAPHYLOKINASE; STAPYLOCOCCUS PROTEIN A; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; BORRELIA; COMPLEMENT ACTIVATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOST PATHOGEN INTERACTION; HOST RANGE; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYME DISEASE; MENINGITIS; NECROTIZING FASCIITIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PHARYNGITIS; PNEUMOCOCCAL INFECTION; PNEUMONIA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SEPTICEMIA; SIALYLATION; SPIROCHETE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PYOGENES; TRANSCRIPTION REGULATION; TREPONEMA; BACTERIAL INFECTION; BACTERIUM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; REVIEW;

BACTERIA (MICROORGANISMS);

BACTERIA; BACTERIAL INFECTIONS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; PHAGOCYTOSIS;

EID: 75649152467     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1601-3_3     Document Type: Article

References (153)

1. Walport MJ. Complement. First of Two parts. N Engl J Med 2001; 344(14):1058-1066.
2. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344(15):1140-1144.
3. Gasque P. Complement: A unique innate immune sensor for danger signals. Mol Immunol 2004; 41(11):1089-1098. (Pubitemid 39345390)
4. Song WC, Sarrias MR, Lambris JD. Complement and innate immunity. Immunopharmacology 2000; 49(1-2):187-198. (Pubitemid 30445229)
5. Ramm LE, Whitlow MB, Mayer MM. Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8 and C9 molecules required for a single channel. Proc Natl Acad Sci USA 1982; 79(15):4751-4755.
6. Kirkitadze MD, Barlow PN. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 2001; 180:146-161. (Pubitemid 32472859)
7. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev 2001; 180:35-48. (Pubitemid 32472850)
8. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332(6166):738-740.
9. Dodds AW, Sim RB, Porter RR et al. Activation of the first component of human complement (C1) by antibody-antigen aggregates. Biochem J 1978; 175(2):383-390. (Pubitemid 9060097)
10. Sim RB, Laich A. Serine proteases of the complement system. Biochem Soc Trans 2000; 28(5):545-550.
11. Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4 Protein Sci 1997; 6(2):263-274. (Pubitemid 27079917)
12. Matsushita M, Fujita T. Ficolins and the lectin complement pathway. Immunol Rev 2001; 180:78-85. (Pubitemid 32472854)
13. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev 2004; 198:185-202. (Pubitemid 38406944)
14. Holmskov U, Thiel S, Jensenius Je. Collections and ficolins: humorallectins of the innate immune defense, Annu Rev Immunol 2003; 21:547-578. (Pubitemid 37174541)
15. Matsushita M, Fujita T. Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology 1995; 194(4-5):443-448.
16. Krarup A, Wallis R, Presanis JS et al. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2 PLoS ONE 2007; 2(7):e623.
17. Ponnuraj K, Xu Y,Macon K et al. Structural analysisof engineered Bb fragment of complement facror B: Insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell 2004; 14(1):17-28. (Pubitemid 38469906)
18. Xu Y, Narayana Sv, VolanakisJE. Structural biology of the alternative pathway convertase, Immunol Rev 2001; 180:123-135. (Pubitemid 32472857)
19. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Bioi Chem 2006; 281(4):2128-2132. (Pubitemid 43845802)
20. Janssen BJ, Huizinga EG, Raaijmakers HC et al. Structures of complement component C3 provide insighrs into the function and evolution of immunity. Nature 2005; 437(7058):505-511. (Pubitemid 41613542)
21. Lambris JD. The multitunctional role of C3, the third component of complement. Immunol Today 1988; 9(12):387-393.
22. Pangburn MK, Rawal N. Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 2002; 30(Pt 6):1006-1010. (Pubitemid 36002396)
23. Rawal N, Pangburn MK. Structure/function of CS convertases of complement. Int Immunopharmacol 2001; 1(3):415-422.
24. Joiner K, Brown E, Hammer C et al. Studies on the mechanism of bacterial resistance to complement-mediated killing. Ill. C5b-9 deposits stably on rough and Type 7S. pneumoniae without causing bacterial killing. J Immunol1983; 130(2):845-849. (Pubitemid 13186316)
25. Davies A, Lachmann PJ. Membrane defence against complement lysis: The structure and biological properties of CD 59 Immunol Res 1993; 12(3):258-275. (Pubitemid 23357452)
26. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005; 3(12):948-958. (Pubitemid 43078158)
27. Rooijakkers SH, van Kessel KP, van Strijp JA. Staphylococcal innate immune evasion. Trends Microbiol 2005; 13(12):596-601. (Pubitemid 41661341)
28. Rooijakkers SH, van Strijp JA. Bacterial complement evasion. Mollmmunol 2007; 44(1-3):23-32. (Pubitemid 44647108)
29. Silverman GJ, Goodyear CS, Siegel DL. On the mechanism of staphylococcalprotein A imrnunornodulation. Transfusion 2005; 45(2):274-280.
30. Forsgren A, Sjoquist J. "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol 1966; 97(6):822-827.
31. Goward CR, ScawenMD, Murphy JP et al. Molecular evolution of bacterial cell-surface proteins. Trends Biochem Sci 1993; 18(4):136-140. (Pubitemid 23105315)
32. Zhang L. Jacobsson K. VasiJ et al. A second IgG-binding protein in Staphylococcus aureus, Microbiology 1998; 144{Pt 4):985-991. (Pubitemid 28187924)
33. Burman J. Leung E. Isenman DE et al. Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein. Mol Immunol 2007; 44(16):3982
34. Rooijakkers SH. van Wamel WJ. Ruyken M et al. Anti-opsonic properties of staphylokinase. Microbes Infect 2005; 7(3):476-484. (Pubitemid 40603446)
35. Harpel PC. Sullivan R. Chang TS. Binding and activation of plasminogen on immobilized immunoglobulin G. Identification of the plasmin-derived Fab as the plasminogen-binding fragment.J Bioi Chem 1989; 264(1):616-624. (Pubitemid 19027651)
36. Seya T. Nagasawa S. Matsukura M et al. Generation of C3d.g and C3d by urokinase-treated plasma in association with fibrinolysis. Complement 1985; 2{2-3):165-174. (Pubitemid 16213819)
37. Fitzgerald JR. Reid SD. Ruotsalainen E et al. Genome diversification in Staphylococcusaureus: Molecular evolution of a highly variable chromosomal region encoding the Staphylococcal exotoxin-like family of proteins. Infect Immun 2003; 71(5):2827-2838. (Pubitemid 36519897)
38. Langley R. Wines B. WilIoughby N et al. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.J Immunol 2005; 174(5):2926-2933. (Pubitemid 40279711)
39. de Haas CI. Veldkamp KE. Peschel A et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent.J Exp Med 2004; 199(5):687-695. (Pubitemid 38316435)
40. Rooijakkers SH. Ruyken M. Roos A et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases, Nat Immunol 2005; 6(9):920-927. (Pubitemid 43090447)
41. Rooijakkers SH. Ruyken M. van RJ et al. Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol2006; 8(8):1282-1293.
42. Rooijakkers SH. Milder FJ. Bardoel BW et al. Staphylococcalcomplement inhibitor: structure and active sites.J Immunol 2007; 179(5):2989-2998.
43. Jongerius I. Kohl J. Pandey MK et al Staphylococcalcomplement evasion by various converrase-blocking molecules. J Exp Med 2007; 204(10):2461-2471. (Pubitemid 47529330)
44. Hammel M. Sfyroera G. Pyrpassopoulos S et al. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus.J Bioi Chern 2007; 282(41):30051-30061. (Pubitemid 350035255)
45. Boden MK. Plock jl, Cloning and characterization of a gene for a 19 kDa fibrinogen-binding protein from Staphylococcus aureus, Mol Microbiol 1994; 12(4):599-606.
46. Hammel M. Sfyroera G. Ricklin D et al.A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol 2007; 8(4):430-437. (Pubitemid 46745418)
47. Lee LY. Liang X. Hook M et al. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Bioi Chem 2004; 279(49):50710-50716. (Pubitemid 40017808)
48. Larva H. Jokiranta TS, Wurzner R et al. Complement resistancemechanismsof streptococci. Mol Inununol 2003; 40(2-4):95-107.
49. Kraiczy P. Wurzner R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 2006; 43:31-44. (Pubitemid 41024919)
50. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets.J Allergy Clin Immunol 2007; 120(1):13-22. (Pubitemid 46990514)
51. Perez-Caballero D. Garda-Laorden 1 Cortes G et al. Interaction between complement regulators and Streptococcus pyogenes: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involves two different cell surface molecules. J Immunol 2004; 173(11):6899-6904. (Pubitemid 39541077)
52. Them A. Stenberg L, Dahlback B et al. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP). a regulatory component of the complement system.J Immunol 1995; 154(1):375-386.
53. Pandiripally V. Gregory E. Cue D. Acquisition of regulators of complement activation by Streptococcus pyogenes serotype M 1 Infect Immun 2002; 70(11):6206-6214. (Pubitemid 35192712)
54. Pandiripally V. Wei L. Skerka C et al. Recruitment of complement factor H-like protein 1 promotes intracellular invasion by group A streptococci. Infect Immun 2003; 71(12):7119-7128. (Pubitemid 37475344)
55. Caswell CC. Han R. Hovis KM et al. The Sell protein of M6-type group A Streptococcus binds the human complement regulatory protein. factor H and inhibits the alternative pathway of complement. Mol Microbiol 2008; 67(3):584-596.
56. Courtney HS. Hasty DL. Dale JB. Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein. Mol Microbiol 2006; 59(3):936-947.
57. Weineisen M. Sjobring U. Fallman M et al. Streptococcal M5 protein prevents neutrophil phagocytosis by interfering with CD11b/CDI8 receptor-mediated association and signaling. J Immunol 2004; 172(6):3798-3807. (Pubitemid 38337965)
58. Lei B, DeLeo FR, Hoe NP et al. Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat Med 2001; 7(12):1298-1305. (Pubitemid 34007933)
59. Akesson P, Sjoholm AG, Bjorck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Bioi Chern 1996; 271(2):1081-1088. (Pubitemid 26034969)
60. Fernie-King BA, Seilly DJ, Willers C et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 2001; 103(3):390-398. (Pubitemid 32626188)
61. Hartas J, Sriprakash KS. Streptococcus pyogenes strains containing emm12 and emm55 possess a novel gene coding for distantly related SIC protein. Microb Pathog 1999; 26(1):25-33. (Pubitemid 29084377)
62. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002; 21(7):1607-1615. (Pubitemid 34614617)
63. von Pawel-Ramrningen U, Bjorck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol2003; 6(1):50-55. (Pubitemid 36258536)
64. Tsao N, Tsai WH, Lin YS et al. Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem Biophys Res Commun 2006; 339(3):779-784. (Pubitemid 41772881)
65. Kuo CF, Lin YS, Chuang WJ et al. Degrading Complement 3 by Streptococcal Pyrogenic Exotoxin B Inhibits Complement Activation and Neutrophil Opsonophagocytosis. Infect Immun 2008; 76(3):1116-1169.
66. Terao Y, Mori Y, YamaguchiM et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Bioi Chem 2008; 283(10):6253-6260.
67. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator, Proc Natl Acad Sci USA 1985; 82(23):8144-8148. (Pubitemid 16171050)
68. Ji Y, McLandsborough L, Kondagunta A et al. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996; 64(2):503-510. (Pubitemid 26032821)
69. Areschoug T, Stalharnmar-CarlernalmM, Karlsson I et al. Streptococcal beta protein has separate binding sites for human factor Hand 19A-Fc. J Bioi Chem 2002; 277(15):12642-12648. (Pubitemid 34952623)
70. Heden LO. Frithz E, Lindahl G. Molecular characterization of an 19A receptor from group B streptococci: sequence of the gene, identification of a proline-rich region with unique structure and isolation ofN-terminal fragments with 19A-binding capacity. Eur J Immuno11991; 21(6):1481-1490.
71. Chmouryguina I, Suvorov A, Ferrieri P et al. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun 1996; 64(7):2387-2390. (Pubitemid 26226794)
72. BohnsackJF, Chang JK, Hill HR. Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species. Infect Immun 1993; 61(4):1421-1426. (Pubitemid 23099216)
73. Mitchell TJ, Andrew PW; Saunders FK et al. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol Microbiol 1991; 5(8):1883-1888. (Pubitemid 21896220)
74. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 1984; 43(3):1085-1087. (Pubitemid 14192004)
75. McDaniel LS, Yother J, Vijayakumar M et al. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987; 165(2):381-394. (Pubitemid 17019822)
76. Dave S, Brooks-Waiter A, Pangburn MK et al. Pspc' a pneumococcal surface protein, binds human factor H. Infect Immun 2001; 69(5):3435-3437. (Pubitemid 32332245)
77. Jarva H, Janulczyk R, Hellwage J et al. Streptococcus pneumoniae evades complement attack and opsonophagocyrosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol 2002; 168(4):1886-1894. (Pubitemid 34135790)
78. Kerr AR, Paterson GK, McCluskey J et al. The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect Immun 2006; 74(9):5319-5324. (Pubitemid 44300451)
79. Li J, Glover DT, Szalai AJ et al. PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun 2007; 75(12):5877-5885. (Pubitemid 350207827)
80. Merino S, Camprubi S, Alberti S et al. Mechanisms of Klebsiella pneumoniae resistance to complement- mediated killing. Infect Immun 1992; 60:2529-2535.
81. Alberti S, Marques G, Hernandez-Alles S et al. Interaction between complement subcomponent Clq and the Klebsiella pneumoniae porin OmpK 36 Infect Immun 1996; 64:4719-4725. (Pubitemid 26357083)
82. Merino S, Nogueras MM, Aguilar A et al. Activation of the complement classicalpathway (Clq binding) by mesophilic Aeromonas hydrophila outer membrane protein. Infect Immun 1998; 66:3825-3831. (Pubitemid 28347843)
83. Clas F, Loos M. Antibody-independent binding of the first component of complement (Cl) and its subcomponent Clq to the Sand R forms of Salmonella minnesota. Infect Immun 1981; 31:1138-1144. (Pubitemid 11155481)
84. Tomas JM. Camprubi S. Merino S et al. Surface exposure of O I serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens. Infect Immun 1991; 59:2006-2011.
85. Alberti S. Marques G. Camprubi S et al. Clq binding and activation of the complement classicalpathway by Klebsiella pneumoniae outer membrane proteins. Infect Immun 1993; 61:852-860. (Pubitemid 23059640)
86. Eisenschenk FC. Houle JJ. Hoffmann EM. Mechanism of serum resistance among Brucella abortus isolates. Vet Microbiol 1999; 68:235-244. (Pubitemid 29459028)
87. Peak IR. Jennings MP. Hood DW et al. Tetrameric repeat units associated with virulence factor phase variation in Haemophilus also occur in Neisseria spp. and Moraxella cararrhalis. FEMS Microbiol Letr 1996; 137:109-114. (Pubitemid 26120876)
88. Peak IR. Jennings MP. Hood DW et al. Terranucleotide repeats ident ify novel virulence determinant homologues in Neisseria meningitidis. Microb Pathog 1999; 26:13-23. (Pubitemid 29084376)
89. Saunders NJ. Peden JF, Hood DW et al. Simple sequence repeats in the Helicobacrer pylori genome. Mol Microbiol 1998; 27:1091-1098. (Pubitemid 28137962)
90. Mandrell RE. ApicellaMA. Lipo-o ligosaccharides (LOS) of mucosal pathogens : molecular mimicry and host-modification of LOS. Immunobiology 1993; 187:382-402. (Pubitemid 23150780)
91. Mandrell RE. GriffissJM. Macher BA. Lipooligosaccharides (LOS) of Neisseriagonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens, Carbohydrate sequence speciticiry of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J Exp Med 1988; 168:107-126.
92. Yuki NK. Susuki M. Koga Y et al. Carbohydrate mimicry between human ganglioside GMl and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Nad Acad Sci USA 2004; 10I: 11404-11409.
93. Edwards JL. Apicella MA. The role of lipooligosaccharide in Neisseria gonorrhoeae pathogenesis of cervical epithelia: Lipid A serves as a C3 acceptor molecule. Cell Microbiol 2002 ; 4:585-598 .
94. Ho DK. Ram S. Nelson KL et al. lgtC expression modulates resistance to C4b deposition on an invasive nonr ypeable Haemophilus inRuenzae. J Immunol 2007; 178:1002-1012. (Pubitemid 46098856)
95. Lewis LA. Ram S. Prasad A et al. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun 2008 ; 76:339-350.
96. Ram S. Cox AD. Wright JC et al. Neisseriallipooligosaccharide is a target for complement component C4b: Inner core phosphoerhanolarnine residues define C4b linkage specificity, J Biol Chern 2003 ; 278:50853-50862. (Pubitemid 38020315)
97. Madico G. Ngampasutadol J. Gulati S et al. Factor H Binding and Function in Sialylated Pathogenic Neisseriae is Influenced by Gonococcal. but Not Meningococcal. Porin , J Immunol 200 7; 178:4489-4497. (Pubitemid 46492401)
98. Hong YQ, Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components Clq and C 3 Clin Immunol Imrnunopathol 1992; 62:133-138 .
99. Wolf U. Bauer D. Traub WH. Meralloprorea ses of Serratia liquefaciens: degradat ion of purified human serum proteins. Zentralbl Bakteriol 1991; 276:16-26.
100. Molla A. Akaike T. Maeda H. Inactivation of various proteina se inhibitors and the complement system in human plasma by the 56-kilodalton proteinase from Serratia marcescens. Infect Immun 1989; 57:1868-18 71. (Pubitemid 19140158)
101. Sodeinde OA. Subrahmanyam YV,Stark K et al. A surface prote ase and the invasivecharacter of plague. Science 1992; 258:1004-1007.
102. Jagels MA. TravisJ. Potempa J et al. Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from Porphyromonas gingivalis. Infect Immun 1996; 64:1984-1991. (Pubitemid 26165656)
103. Discipio RG. Daffern PJ. Kawahara M et al. Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation of C5 augments proteinase digestion of C 5 Immunology 1996; 87:660-667.
104. Jagels MA. Ember JA. Travis J et al. Cleavage of the human C5A reccptor by proteinases derived from Porphyromonas gingivalis : Cleavage of leukocyte C5a reccptor. Adv Exp Med BioI 1996; 389:155-164.
105. Schenkein HA. Pletcher HM. Bodnar M et al. Increased opsonizat ion of a prtH-defective mutant of Porph yromonas gingivalis W83 is caused by reduced degradation of complement-derived opsonins . J Immunol 1995; 154:5331-5337 .
106. Grenier D. Inactivation of human serum bactericidal activity by a tryp sinlike prote ase isolated from Porph yromonas gingivalis. Infect Immun 1992; 60:1854-1857.
107. Popadiak K. Porernpa J. Riesbeck K et al. Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol 2007; 178:7242-7250. (Pubitemid 46847450)
108. Wingrove JA. DiScipio RG. Chen Z et al. Activation of complement component s C3 and C5 by a cysteine proteinase (gingipain-I) from Porphyromonas (Bacteroides) gingivalis. J BioI Chern 1992; 267: 18902-18907.
109. Slaney JM, Curtis MA. Mechanisms of evasion of complement by Porphyromonas gingWalis. Front Biosci 2008; 13:188-196. (Pubitemid 351594770)
110. Slaney JM, Gallagher A, Aduse-Opoku J et al. Mechanisms of resistance of Porphyromonas gingivalis to killing by serum complement. Infect Irnrnun 2006; 74:5352-5361. (Pubitemid 44300455)
111. Lathern WW; Price PA, Miller VL et al. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007; 315:509-513. (Pubitemid 46175753)
112. Blom AM, Rytkonen A. Vasquez P et al. A novel interaction between Type IV pili of Neisseria gonorrhoeae and the human complement regulator C4B-binding protein. J Immunol 2001; 166:6764-6770. (Pubitemid 32467221)
113. Ram S. Cullinane M. Blom A et al. Binding of C4b-binding Protein to Porin: A molecular mechanism of serum resistance of Neisseria gonorrhoeae. J Exp Med 2001; 193:281-296.
114. Nordstrom T. Blom AM, Forsgren A et al. The emerging pathogen Moraxella cararrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins Al and A 2 J Immunol 2004; 173:4598-4606. (Pubitemid 39280693)
115. Attia AS. Ram S, Rice PA et al. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun 2006; 74:1597-1611. (Pubitemid 43346793)
116. Ngampasutadol J, Ram S, Blom AM et al. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Nacl Acad Sci USA 2005; 102:17142-17147. (Pubitemid 41692697)
117. Arko RJ. Kraus SJ, Brown WJ et al. Neisseria gonorrhoeae: effects of systemic immunization on resistance of chimpanzees to urethral infection. J Infect Dis 1974; 130:160-164.
118. Stevenson B, El-Hage N. Hines MA et al. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun 2002; 70:491-497. (Pubitemid 34083805)
119. Bartra SS, Sryer KL, O'Bryant DM et al. Resistance ofYersinia pestis to Complement-Dependent Killing is Mediated by the Ail Outer Membrane Protein. Infect Immun 2008; 76 (2): 612-622. (Pubitemid 351251731)
120. Heffernan EJ, Reed S. Hackett Jet al. Mechanism of resistance to complement-mediated killing ofbacteria encoded by the Salmonella typhimurium virulence plasmid gene rck. J Clin Invest 1992; 90:953-964.
121. Bliska JB. Falkow S. Bacterial resistance to complement killing mediated by the Ail protein of Yersinia enterocolirica. Proc Nacl Acad Sci USA 1992; 89:3561-3565.
122. Joiner KA, Hammer CH. Brown EJ et al. Studies on the mechanism of bacterial resistance to complement- mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota 5218 without causing bacterial death. J Exp Med 1982; 155:797-808. (Pubitemid 12187853)
123. Joiner KA. Hammer CH, Brown EJ et al. Studies on the mechanism of bacterial resistance to complement-mediated killing. 11 C8 and C9 release C5b67 from the surface of Salmonella minnesota 5218 because the terminal complex does not insert into the bacterial outer membrane. J Exp Med 1982; 155:809-919.
124. Joiner KA, Warren KA. Hammer C et al. Bactericidal but not non bactericidal C5b-9 is associated with distinctive outer membrane proteins in Neisseria gonorrhoeae. J Immunol 1985; 134:1920-1925. (Pubitemid 15128961)
125. Pfeiffer R. Z Hyg Infektionskr 1895; 20:215.
126. Thomas L, Dingle JH. Investigations of meningococcal infection. Ill. Bactericidal action of normal and immune sera for the meningococcus. J Clin Invest 1943; 22:375-385.
127. Jarvis GA, Griffiss JM. Human IgAl blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol 1991; 147:1962-1967.
128. Selander B. KayhtyH, Wedege E et al. Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae Type b in two C2-deficient sisters: Alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG. J Clin Immunol 2000; 20: 138-149. (Pubitemid 30314318)
129. Hall WH. Manion RE, Zinneman HH. Blocking serum lysis of Brucella abortus by hyperimmune rabbit immunoglubulin A. J Immunol 1971; 107:41-46.
130. Glenchur H, Hall WH. Zinneman HH. Blocking antibodies in rabbits infected with Brucella melitensis. Proc Soc Exp BioI Med 1959; 101:422-425.
131. Guccman RM. Waisbren BA. Bacterial blocking activity of specific IgG in chronic Pseudomonas aeruginosa infection. Clin Exp Immuno11975; 19:121-130.
132. Waisbren BA, Brown I. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J Immunol 1966; 97:431-437.
133. Joiner KA. Scales R. Warren KA et al. Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. J Clin Invest 1985; 76:1765-1772. (Pubitemid 16196043)
134. Plummer FA. Chubb H. Simonsen IN et al. Antibody to Rmp (outer membrane protein 3) increases susceptibility to gonococcal infection. J Clin Invest 1993; 91:339-343. (Pubitemid 23037289)
135. Kraiczy P. Skerka C, Brade V et al. Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun 2001; 69(12):7800-7809. (Pubitemid 33086611)
136. Alitalo A, Meri T, Lankinen H et al. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol 2002; 169(7):3847-3853.
137. Pausa M, Pellis V, Cinco M et al. Serum-resistant strains of Borrelia burgdorferi evade complement- mediated killing by expressing a CD59-like complement inhibitory molecule. J Immunol 2003; 170(6) :3214-3222. (Pubitemid 36302199)
138. McDowellJV, WolfgangJ, Tran E et al. Comprehensive analysis of the factor h binding capabilities of borrelia species associated with lyrne disease: Delineation of two distinct classes of factor H binding proteins. Infect Immun 2003; 71(6):3597-3602. (Pubitemid 36637589)
139. Hovis KM, MeDowellJY, Griffin L et al. Identification and characterization of a linear-plasmid-encoded factor H-binding protein (FhbA) of the relapsing fever spirochete Borrelia hermsii. J Bacteriol 2004; 186(9):2612-2618. (Pubitemid 38525914)
140. Meri T, Cuder SJ,BlomAM et al. RelapsingfeverspirocheresBorrelia recurrentis and B. Duttonii acquire complement regulators C4b-binding protein and factor H. Infect Immun 2006; 74(7):4157-4163. (Pubitemid 43993349)
141. McDowell JV, Frederick J, Starnm L et al. Identification of the gene encoding the FhbB protein of Treponema denticola, a highly unique factor H-like protein 1 binding protein. Infect Immun 2007; 75(2): 1050-1054. (Pubitemid 46203472)
142. McDowell JV, Lankford J, Stamm L et al. Demonstration of factor H-like protein 1 binding to Treponema denticola, a pathogen associated with periodontal disease in humans. Infect Immun 2005; 73(11):7126-7132. (Pubitemid 41587609)
143. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nat Rev Immunol 2008; 8(1):48-58.
144. Marr N, Luu RA, Fernandez RC. Bordetella pertussis binds human Cl esterase inhibitor during the virulent phase, to evade complement-mediated killing.J Infect Dis 2007; 195:585-588. (Pubitemid 46214402)
145. China B, Sory MP, N'Guyen BT et al. Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules. Infect Immun 1993; 61:3129-3136. (Pubitemid 23223396)
146. Ram S, McQuillen DP, Gulati S et al. Binding of complement factor H to loop 5 of porin protein lA: A molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 1998; 188:671-680. (Pubitemid 28387930)
147. Madico G, Welsch JA, Lewis LA et al. The meningococcalvaccinecandidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.J Immunol 2006; 177:501-510. (Pubitemid 43939163)
148. Kunert A, Losse J, Gruszin C et al. Immune evasion of the human pathogen Pseudomonas aeruginosa: Elongation factor Tuf is a factor H and plasminogen binding protein. J Immunol 2007; 179:2979-2988.
149. Prasadarao NV, Blom AM, Villoutreix BO et al. A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K 1 J Immunol 2002; 169:6352-6360. (Pubitemid 36903483)
150. Berggard K, Johnsson E, Mooi FR et al. Bordetella pertussis binds the human complement regulator C4BP: Role of filamentous hemagglutinin. Infect Immun 1997; 65:3638-3643. (Pubitemid 27398118)
151. Jarva H, Ram S, Vogel U et al. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol 2005; 174:6299-6307. (Pubitemid 40663822)
152. Hallstrom T, Iarva H, RiesbeckK et al. Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol 2007; 178:6359-6366. (Pubitemid 46717420)
153. Hallstrom T, TrajkovskaE, Forsgren A et al. Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. J Immunol 2006; 177:430-436. (Pubitemid 43939155)